Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11195-11201

  Katou, Fuminori ^a   Ohtani, Haruo ^b   Watanabe, Yoshiko ^a   Nakayama, Takashi ^c   Yoshie, Osamu ^c   Hashimoto, Kenji ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION MITO MEDICAL CENTER   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CD69 ANTIGEN; KI 67 ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN PD 1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CONTROLLED STUDY; FROZEN SECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LICHEN PLANUS; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STROMA CELL; TISSUE DISTRIBUTION; TONGUE CANCER; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; APOPTOSIS REGULATORY PROTEINS; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KI-67 ANTIGEN; KILLER CELLS, NATURAL; LICHEN PLANUS, ORAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; PHENOTYPE; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS; T-LYMPHOCYTES, CYTOTOXIC; TONGUE; TONGUE NEOPLASMS;

EID: 37049020929     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2637     Document Type: Article

References (36)

1. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-27.
2. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
3. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
4. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
5. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 2007;204:345-56.
6. Moretta A, Poggi A, Pende D, et al. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor α/β. J Exp Med 1991;174:1393-8.
7. Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E, et al. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993;178:537-47.
8. North J, Bakhsh I, Marden C, et al. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol 2007;178:85-94.
9. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
10. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7.
11. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001;1:41-9.
12. Zhang C, Zhang J, Wei H, Tian Z. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity? Int Immunopharmacol 2005;5:1099-111.
13. Brooks AG, Posch PE, Scorzelli CJ, Borrego F, Coligan JE. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J Exp Med 1997;185:795-800.
14. Masilamani M, Nguyen C, Kabat J, Borrego F, Coligan JE. CD94/NKG2A inhibits NK cell activation by disrupting the actin network at the immunological synapse. J Immunol 2006;177:3590-6.
15. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-9.
16. Smyth MJ, Swann J, Cretney E, et al. NKG2D function protects the host from tumor initiation. J Exp Med 2005;202:583-8.
17. Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002;13:350-65.
18. + T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol 2003;163:261-8.
19. Katou F, Ohtani H, Nakayama T, et al. Macrophage-derived chemokine (MDC/CCL22) and CCR4 are involved in the formation of T lymphocyte-dendritic cell clusters in human inflamed skin and secondary lymphoid tissue. Am J Pathol 2001;158:1263-70.
20. + mature dendritic cells in human lymph node versus chronically inflamed skin. J Pathol 2003;199:98-106.
21. Santoro A, Majorana A, Bardellini E, et al. Cytotoxic molecule expression and epithelial cell apoptosis in oral and cutaneous lichen planus. Am J Clin Pathol 2004;121:758-64.
22. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-39.
23. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465-72.
24. Tsushima F, Tanaka K, Otsuki N, et al. Predominant expression of B7-1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol 2006;42:268-74.
25. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-7.
26. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
27. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
28. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17:19-29.
29. Groh V, Smythe K, Dai Z, Spies T. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 2006;7:755-62.
30. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002;8:3137-45.
31. + T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 2004;91:1711-7.
32. Speiser DE, Pittet MJ, Valmori D, et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med 1999;190:775-82.
33. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
34. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
35. Jewett A, Head C, Cacalano NA. Emerging mechanisms of immunosuppression in oral cancers. J Dent Res 2006;85:1061-73.
36. + T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-6.